Clinical Supply Regulatory Articles

31. Inside GCSG 2026: Clinical Supply Impact On Patient Experience 5/21/2026

    This GCSG 2026 event recap with Steve Jacobs (including video) highlights how clinical testing and supply decisions shape patient experience, among other buzzy topics.

32. U.S. Policy Drift And The Shift In Clinical Trial Supply Leadership 5/21/2026

    China's clinical trial system now outpaces the U.S., exposing regulatory delays that ripple into supply planning, manufacturing windows, and drug development speed. 

33. From Individual Shipments To Patterns: How Compliance Is Understood Over Time 5/13/2026

    Compliance shifts from single shipments to patterns over time. Consistency in identity, documentation, and rationale reveals structure that makes decisions traceable.

34. At The Point Of Review: How Clinical Shipments Are Evaluated In Practice 5/6/2026

    At review, clinical shipments become a single consolidated record. Delays arise when relationships between product identity, classification, and documentation are unclear.

35. The cGMP Reality Of Clinical Supply For Advanced Therapies 5/5/2026

    Breakthrough therapies fail without cGMP‑ready supply. In cell and gene therapies, quality systems, timing, documentation and logistics dictate patient access.

36. How Clinical Supply Drives Resilience In Global Vaccine Networks 4/29/2026

    This article is the first in a two-part series exploring how clinical supply's ability to integrate processes drives resilience in global vaccine programs.

37. From Inconsistency To Structure: A Model For Defensible Compliance Decisions 4/29/2026

    Compliance decisions depend on how sponsors, manufacturers, logistics, and brokers align inputs. Structure connects documentation, reducing reconstruction at review.

38. Why Good Data Still Fails: Inconsistency, Visibility, And Decision Risk 4/22/2026

    Even with strong visibility clinical supply chains face delays when data is inconsistent across systems. Alignment not more data drives faster, clearer border decisions.

39. When Shipments Stop: Understanding And Managing Customs Delays In Clinical Supply Chains 4/15/2026

    Customs delays aren’t random disruptions. They reveal where documentation, classification, and context fail to align under scrutiny across complex global trials.

40. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.